Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Is insurance coverage of pricey glucagon-like peptide 1 (GLP-1) receptor agonists for obesity about to increase dramatically? Advocates of the anti-obesity medications are hopeful, especially if the ...

The National Academy of Sports Medicine® (NASM), the global leader in fitness and wellness training and certifications, is launching its latest course, "Understanding Weight Loss Medications: A Guide ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in ...

On Wednesday, state house lawmakers were considering House Bill 1451, which was seeking to require Medicaid to provide ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.